The buck stops ear: Hear­ing loss biotech to look for 's­trate­gic op­tion­s' as da­ta analy­ses prove fruit­less

A Cal­i­for­nia biotech fo­cused on de­vel­op­ing treat­ments for neu­ro­log­i­cal con­di­tions of the ear ap­pears to be think­ing about clos­ing up shop.

San Diego-based Oton­o­my said Thurs­day it would “ex­plore strate­gic op­tions,” code for sell­ing all its as­sets and pos­si­bly it­self, af­ter one of its ear com­pounds did not im­prove pa­tients’ hear­ing loss in a clin­i­cal analy­sis. The de­ci­sion comes two months af­ter a sep­a­rate pro­gram failed a Phase II test, which slashed its stock price $OT­IC more than 70% at the time.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER